Risk of Bone Mineral Density Loss Associated with GLP-1 Receptor Agonists in Overweight COPD Populations [Letter]
Yiwen Hong, Jia Liu · 2026
Read Risk of Bone Mineral Density Loss Associated with GLP-1 Receptor Agonists in Overweight COPD Populations [Letter] by Yiwen Hong, Jia Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13401917.txt.
Description
Yiwen Hong and Jia Liu wrote a 2026 letter on a study by Huang and co-authors. It reported that GLP-1 receptor agonists, the popular weight-loss and diabetes drugs, lowered death and adverse event rates in patients who have both COPD and obesity. The findings could matter clinically, but the letter raises two cautions before the drugs are recommended to this group.
The first caution is bone health. The original study did not evaluate osteoporosis or fracture risk at all, even though COPD patients already carry an elevated risk of thinning bones from several directions at once. Losing substantial weight on these drugs could add to that danger. The writers argue that any recommendation for GLP-1 treatment in obese COPD patients should wait for bone density results to be measured with the heart and lung benefits already reported.
Catalog record
| CREATOR | Yiwen Hong, Jia Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 5309 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |